2251 GMT - Healius could return some A$300 million to its shareholders from selling its imaging business Lumus, reckons Citi. Healius in September said it would sell Lumus to Affinity Equity Partners for A$965 million, but didn't specify how much of the proceeds would be returned to shareholders. Analyst Mathieu Chevrier thinks it could involve Healius declaring a special dividend of A$0.40/share. "We upgrade to Neutral on recent share price decline, sale of Lumus which will make Healius debt-free, and a pathology cost base now likely more reflective of true business-as-usual costs," Citi says. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
November 19, 2024 17:52 ET (22:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.